Allogene Therapeutics, Inc. (ALLO) › Operating IncomeAllogene Therapeutics, Inc. (ALLO) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2018: -$192.84M2019: -$202.01M2020: -$258.24M2021: -$180.19M2022: -$335.54M2023: -$327.74M2024: -$273.20M2025: -$209.31M-$209.31M2018Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$209.31M+23.4%2024-$273.20M+16.6%2023-$327.74M+2.3%2022-$335.54M-86.2%2021-$180.19M+30.2%2020-$258.24M-27.8%2019-$202.01M-4.8%2018-$192.84M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share